CorDynamics has expertise in multiple 'gold-standard' methods to study the pathology of pulmonary arterial hypertension (PAH) and investigate potential therapies.
Monocrotaline-Induced PAH Model
Using the in vivo rat model, responses to compounds can be evaluated in both prevention and reversal modes.
Hypoxia + VEGF-Antagonist Induced PAH Model
Using the rat model, test articles can be interrogated in the most robust small animal preclinical model available.
Because pulmonary arteries constrict in response to hypoxia in order to divert blood to more ventilated areas of the lungs, this physiologic phenomenon can be exploited to assess selectivity of test articles on pulmonary versus systemic arteries.
CorDynamics collaborates with clients on all their drug discovery steps, with an eye on eventual regulatory compliance.